Loading...
Guest User
Welcome! Please login.
| IPO Listing At | BSE, NSE |
| IPO Issue Type | Book Build Issue |
| Issue Size | ₹165.00 Cr |
| Fresh Issue | ₹90.00 Cr |
| Offer for Sale | ₹75.00 Cr |
| Face Value | ₹5 Per Equity Share |
| Price Band | ₹75.00-79.00 per share |
| BSE Code | 544709 |
| NSE Code | GAUDIUMIVF |
| Registrar | Bigshare Services Pvt.Ltd. |
| Lead Managers | Sarthi Capital Advisors Pvt.Ltd. |
Disclaimer: GMP is sourced from grey market dealers and is indicative only. Always conduct your own due diligence.
* Allotment, Refund, Demat Credit & Listing dates are tentative and subject to change.
Minimum bid: 189 shares and in multiples thereof
Gaudium IVF and Women Health Limited is an India-based fertility care provider specializing in In Vitro Fertilization (IVF) and related reproductive treatments. The company operates through a hub-and-spoke model and has expanded its presence across multiple states, with more than thirty centers comprising seven main hubs and twenty-eight spoke clinics. It has also formed strategic partnerships with infertility experts to increase awareness and access to Assisted Reproductive Technology (ART) and IVF services.
Gaudium serves both domestic and international patients from countries such as Canada, the United Kingdom, the United States, Kenya, South Africa, and Oman. Its key centers are located in major cities including Delhi (Janakpuri and Kailash Colony), Mumbai (Khar West), Ludhiana, Srinagar, Patna, and Bangalore.
The company provides a wide range of fertility treatments, including IVF, ICSI, IUI, and ovulation induction, addressing infertility challenges in both men and women. It also offers gynecological care for conditions such as PCOS/PCOD and endometriosis, along with specialized management for high-risk pregnancies. Additionally, the centers provide advanced male infertility treatments, including specialized sperm retrieval procedures.
Key strengths:
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Funding capital expenditure towards establishment of New IVF Centers of the Company. | 50.00 |
| 2 | Repayment/pre-payment, in full or in part, of certain outstanding loans availed by the Company. | 20.00 |
| 3 | General Corporate Purposes | 12.28 |
| 4 | Issue Expenses | 14.15 |
| Total | 96.43 |
| Period Ended | 30 Sep 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 106.62 | 88.51 | 51.01 | 36.63 |
| Total Income | 49.75 | 70.96 | 48.15 | 44.26 |
| Profit After Tax | 12.51 | 19.13 | 10.32 | 13.53 |
| EBITDA | 18.95 | 28.63 | 19.27 | 20.07 |
| NET Worth | 58.85 | 46.30 | 26.99 | 22.73 |
| Reserves and Surplus | 28.16 | 15.60 | 26.00 | 21.74 |
| Total Borrowing | 22.51 | 18.93 | 15.73 | 9.78 |
| Amount in ₹ Crore | ||||
| KPI | Sep 30, 2025 | Mar 31, 2025 |
|---|---|---|
| ROE | 21.25% | 41.31% |
| ROCE | 21.03% | 39.70% |
| Debt / Equity | 0.38% | 0.41% |
| RoNW | 21.34% | 41.71% |
| PAT Margin | 25.14% | 26.96% |
| EBITDA Margin | 38.29% | 40.48% |
| Price to Book Value | 10.48 |
| Metric | Pre IPO | Post IPO |
|---|---|---|
| EPS (₹) | 3.12 | 3.44 |
| P/E (x) | 25.36 | 22.99 |
| Promoter Holding | 99.99% | 71.30% |
| Market Cap | ₹575.02 Cr. | |
